Role of Flow Cytometry in the Diagnosis of Chronic Granulomatous Disease: the Egyptian Experience

. 2016 Aug ; 36 (6) : 610-8. [epub] 20160524

Jazyk angličtina Země Nizozemsko Médium print-electronic

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/pmid27222152
Odkazy

PubMed 27222152
DOI 10.1007/s10875-016-0297-y
PII: 10.1007/s10875-016-0297-y
Knihovny.cz E-zdroje

INTRODUCTION: Chronic granulomatous disease (CGD) is an inherited mutational defect in any of the NADPH oxidase complex, CYBB (gp91-phox), NCF1 (p47-phox), CYBA (p22-phox), NCF2 (p67-phox), or NCF4 (p40-phox) leading to inability of phagocytes to perform effective respiratory burst and thus diminished killing of bacteria and fungi. The identification of defective proteins aids in establishing a diagnosis prior to genetic analysis, which is rather labor-intensive, expensive, and time-consuming. AIM: The present study aims at assessing the NADPH proteins by performing the intracellular staining with specific monoclonal antibodies and their assessment on flow cytometry. The use of flow cytometry is less laborious and faster to perform than western blot. It also confirms the diagnosis of CGD and detects the affected components allowing proper management of patients. MATERIALS AND METHODS: Twenty-eight patients from 25 different kindred, clinically suspected as CGD were recruited in Egypt. Dihydrorhodamine test was performed to confirm the diagnosis of the patients. Intracellular staining of NADPH components using specific monoclonal antibodies was performed followed by flow cytometric analysis. RESULTS: The present study revealed that the most common defective protein in our cohort is p22-phox, found in 13 patients (46.4 % of cases) followed by p47-phox in 8 patients (28.6 %), gp91-phox in 5 patients (17.9 %), and finally p67-phox in 2 patients (7.1 %). CONCLUSION: In countries with limited resources and yet large number of CGD patients, the analysis of the defective proteins by flow cytometry is an optimum solution for confirming the diagnosis and is a step for targeted sequencing in families seeking prenatal diagnosis.

Zobrazit více v PubMed

Eur J Clin Invest. 2009 Apr;39(4):311-9 PubMed

J Hum Genet. 2006;51(10):887-95 PubMed

Br J Haematol. 2008 Jun;141(6):848-51 PubMed

J Clin Immunol. 2014 May;34(4):452-8 PubMed

Blood Cells Mol Dis. 2000 Oct;26(5):561-5 PubMed

Expert Rev Anti Infect Ther. 2012 Aug;10(8):881-94 PubMed

Clin Immunol. 2008 Oct;129(1):103-14 PubMed

J Immunol Methods. 1996 May 27;191(2):187-96 PubMed

Clin Immunol. 2008 Aug;128(2):117-26 PubMed

J Allergy Clin Immunol. 2013 Nov;132(5):1156-1163.e5 PubMed

Clin Rev Allergy Immunol. 2010 Feb;38(1):3-10 PubMed

Iran J Allergy Asthma Immunol. 2005 Jun;4(2):103-6 PubMed

N Engl J Med. 2010 Dec 30;363(27):2600-10 PubMed

Hum Mutat. 2006 Dec;27(12):1218-29 PubMed

Clin Chem. 2007 May;53(5):890-6 PubMed

Hum Mutat. 2008 Sep;29(9):E132-49 PubMed

Blood. 1994 Oct 15;84(8):2767-75 PubMed

J Korean Med Sci. 2009 Dec;24(6):1045-50 PubMed

J Clin Immunol. 2013 Nov;33(8):1276-84 PubMed

J Clin Immunol. 2009 Mar;29(2):215-30 PubMed

Allergol Immunopathol (Madr). 2015 May-Jun;43(3):279-85 PubMed

Redox Biol. 2015 Aug;5:358-66 PubMed

Iran J Allergy Asthma Immunol. 2009 Mar;8(1):57-61 PubMed

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...